Agreement termination period upon written notice.

No definition available.

Name:	spro_AgreementTerminationPeriodUponWrittenNotice
Namespace Prefix:	spro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Change in subsequent payments

+ References

No definition available.

+ Details

Name:	spro_ChangeInSubsequentPayments
Namespace Prefix:	spro_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Discount on Obligations.

+ References

No definition available.

+ Details

Name:	spro_DiscountOnObligations
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Initial Payments to Perform the Obligations.

+ References

No definition available.

+ Details

Name:	spro_InitialPaymentsToPerformTheObligations
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement fixed assets related payments.

+ References

No definition available.

+ Details

Name:	spro_LicenseAgreementFixedAssetsRelatedPayments
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreement future milestone payments.

+ References

No definition available.

+ Details

Name:	spro_LicenseAgreementFutureMilestonePayments
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreement milestone payment upon completion and delivery of results of a clinical study.

+ References

No definition available.

+ Details

Name:	spro_LicenseAgreementMilestonePaymentUponCompletionAndDeliveryOfResultsOfClinicalStudy
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreement milestone payments upon achievement of specified clinical, regulatory and commercial milestones.

+ References

No definition available.

+ Details

Name:	spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndCommercialMilestones
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreement milestone payments upon achievement of specified pivotal condition.

+ References

No definition available.

+ Details

Name:	spro_LicenseAgreementMilestonePaymentsUponAchievementSpecifiedPivotalCondition
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License agreement payment of research and development expense related to achievement of regulatory milestones.

+ References

No definition available.

+ Details

Name:	spro_LicenseAgreementPaymentOfResearchAndDevelopmentExpenseRelatedToAchievementOfRegulatoryMilestones
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Allocated Research And Development Services

+ References

No definition available.

+ Details

Name:	spro_MilestoneAllocatedResearchAndDevelopmentServices
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payment upon submission of a new drug application.

+ References

No definition available.

+ Details

Name:	spro_MilestonePaymentUponSubmissionOfANewDrugApplication
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestones payment received

+ References

No definition available.

+ Details

Name:	spro_MilestonesPaymentReceived
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non refundable up front payment received.

+ References

No definition available.

+ Details

Name:	spro_NonRefundableUpFrontPaymentReceived
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Patients

+ References

No definition available.

+ Details

Name:	spro_NumberOfPatients
Namespace Prefix:	spro_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Performance Obligation Allocated Transaction Price

+ References

No definition available.

+ Details

Name:	spro_PerformanceObligationAllocatedTransactionPrice
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Period of option granted on an agreement.

+ References

No definition available.

+ Details

Name:	spro_PeriodOfOptionGrantedOnAgreement
Namespace Prefix:	spro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Receivable amount upon achievement of certain milestone.

+ References

No definition available.

+ Details

Name:	spro_ReceivableAmountUponAchievementOfCertainMilestone
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Remaining milestone payment

+ References

No definition available.

+ Details

Name:	spro_RemainingMilestonePayment
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Remaining Sublicence Fee Paid to Counter Party

+ References

No definition available.

+ Details

Name:	spro_RemainingSublicenceFeePaidToCounterParty
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Remaining Transaction price allocated to performance obligations.

+ References

No definition available.

+ Details

Name:	spro_RemainingTransactionPriceAllocatedToPerformanceObligations
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty Percentage

+ References

No definition available.

+ Details

Name:	spro_RoyaltyPercentage
Namespace Prefix:	spro_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Sales milestone events

+ References

No definition available.

+ Details

Name:	spro_SalesMilestoneEvents
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Significant financing component

+ References

No definition available.

+ Details

Name:	spro_SignificantFinancingComponent
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total milestone

+ References

No definition available.

+ Details

Name:	spro_TotalMilestone
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Total potential additional milestones

+ References

No definition available.

+ Details

Name:	spro_TotalPotentialAdditionalMilestones
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total Received Milestone

+ References

No definition available.

+ Details

Name:	spro_TotalReceivedMilestone
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Upfront payment received.

+ References

No definition available.

+ Details

Name:	spro_UpfrontPaymentReceived
Namespace Prefix:	spro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spro_GskSpaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_ResearchAndDevelopmentServicesRelatedToUpcomingMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_LicenseAndKnowHowTransferMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=spro_VertexLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=spro_GskLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=spro_AmendmentTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_FirstMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=spro_AmendmentFourMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spro_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_SecondMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_ThirdMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_FourthMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=spro_MeijiLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=spro_EverestLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_SPRTwoZeroSixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=spro_SPRSevenFourOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=spro_PfizerLicenseAndSharePurchaseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License, Collaboration and Service Agreements - Additional Information (Detail) $ / shares in Units, $ in Thousands			1 Months Ended			3 Months Ended							12 Months Ended
	May 31, 2025 USD ($) Patient	Jan. 15, 2021 USD ($)	Oct. 31, 2021 USD ($)	Jun. 30, 2017 USD ($)	May 31, 2016 USD ($)	Mar. 31, 2026 USD ($) $ / shares	Mar. 31, 2025 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2025 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Feb. 28, 2025 USD ($)	Jan. 31, 2025 USD ($)	Oct. 31, 2024 USD ($)	Aug. 31, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Nov. 07, 2022 USD ($)	Oct. 31, 2017 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of Patients \| Patient	2,637
RoyaltyPercentage	1.00%
Common stock, par value \| $ / shares						$ 0.001							$ 0.001
Revenue recognized						$ 0	$ 12
Total Milestone								$ 95,000
Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sales milestone events	$ 750,000
Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment						750,000
GSK SPA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining transaction price allocated to the performance obligations						64,700
Milestone payment						21,200
Total Milestone						30,000
Initial Payments to Perform the Obligations														$ 66,000
Discount on Obligations														1,300
GSK SPA [Member] \| Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized														19,000
GSK SPA [Member] \| License and Know-How Transfer [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining transaction price allocated to the performance obligations														64,700
Performance Obligation Allocated Transaction Price														$ 45,700
Vertex License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payments					$ 500
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones					$ 80,200
License agreement payment of research and development expense related to achievement of regulatory milestones						0	0
GSK License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of Patients \| Patient	1,690
Performance Obligation Allocated Transaction Price						300	5,100
Milestone payment						225,000
Remaining Milestone Payment						1,100
Total Received Milestone						25,000
Total Milestone													$ 25,000
GSK License Agreement [Member] \| Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development services performance obligation						4,300
GSK License Agreement [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment	$ 150,000
Total Milestone						150,000
GSK License Agreement [Member] \| Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment						1,000,000
GSK License Agreement [Member] \| Amendment 2 [Member] \| Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total potential additional milestones						3,200
GSK License Agreement [Member] \| Amendment 2 [Member] \| First Milestone [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																		$ 1,200
GSK License Agreement [Member] \| Amendment 4 [Member] \| Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total potential additional milestones						800
GSK License Agreement [Member] \| Glaxo Smith Kline [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																						$ 66,000
Reduction In Subsequent Payments by GSK to the Company																						50.00%
GSK License Agreement [Member] \| Glaxo Smith Kline [Member] \| Amendment 2 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																					$ 4,300
GSK License Agreement [Member] \| Glaxo Smith Kline [Member] \| Amendment 2 [Member] \| Second Milestone [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																	$ 1,300
GSK License Agreement [Member] \| Glaxo Smith Kline [Member] \| Amendment 2 [Member] \| Third Milestone [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment															$ 700
GSK License Agreement [Member] \| Glaxo Smith Kline [Member] \| Amendment 2 [Member] \| Fourth Milestone [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment								1,100
GSK License Agreement [Member] \| Glaxo Smith Kline [Member] \| Amendment 4 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																	$ 800
GSK License Agreement [Member] \| GSK SPA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment								64,700											$ 23,800		$ 30,000
Total Received Milestone								95,000												$ 30,000
Significant financing component								2,500
Total Milestone								95,000
Research and development services performance obligation						8,600		2,500
GSK License Agreement [Member] \| GSK SPA [Member] \| Second Milestone [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining Milestone Payment						400
Total Received Milestone																$ 400
Meiji License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payments				$ 600
Potential milestone payments upon achievement of specified condition																							$ 1,000
License agreement fixed assets related payments												$ 1,600
Potential milestone payments upon completion and delivery of results of a clinical study			$ 1,000
Future milestone payments						$ 1,000
Remaining Sublicence Fee Paid to Counter Party								$ 7,500
Everest License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of option granted on an agreement						12 months
Upfront payment received											$ 3,000
Potential milestone payments upon completion and delivery of results of a clinical study										$ 2,000
Milestone payment						$ 34,000
Everest License Agreement [Member] \| SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received											2,000
Milestones payment received		$ 2,000
Everest License Agreement [Member] \| SPR 741 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received											$ 1,000
Everest License Agreement [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		180 days
Everest License Agreement [Member] \| Maximum [Member] \| SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone		$ 38,000				59,500
Everest License Agreement [Member] \| Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		90 days
Pfizer License and Share Purchase Agreements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone									$ 900
Milestones payment received									5,000
Remaining transaction price allocated to the performance obligations						12,500
Revenue recognized							$ 100						12,600
Performance Obligation Allocated Transaction Price									5,000
Remaining Milestone Payment						5,000							$ 5,000
Pfizer License and Share Purchase Agreements [Member] \| Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price						11,100			$ 4,100
Pfizer License and Share Purchase Agreements [Member] \| License and Know-How Transfer [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price						$ 1,400